GW Pharmaceuticals plc (AIM: GWP) today announces that the European Patent Office has granted a patent which protects the composition of the Sativex® formulation. This patent has already been granted in the United States. The patent, entitled “Cannabinoid Liquid Formulations for Mucosal Administration”, provides an exclusivity period until August 2023.
In addition to this newly granted patent, Sativex® is protected by a number of other patents related to different aspects of the product.
Dr Geoffrey Guy, GW’s Chairman, said, “We are very pleased to have further reinforced the patent estate surrounding Sativex. The grant of this patent is part of a matrix of intellectual property rights which continue to be developed by GW, comprising patents, plant variety rights and proprietary know-how, devised to provide extended protection of Sativex and the cannabinoid pipeline.”
Sativex® is approved in the UK, Spain, Denmark, Czech Republic, Canada and New Zealand as a treatment of Multiple Sclerosis spasticity. The product is also in Phase III clinical development as a treatment for cancer pain.
Patent: “Cannabinoid Liquid Formulations for Mucosal Administration”
Patent Number: EP 1542657 / Inventor: Brian Whittle / Patent Abstract: The present invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray.